Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center
International Journal of Environmental Research and Public Health · 2023
DOI: 10.3390/ijerph20105824 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Environmental Research and Public Health, 2023. Verfasst von Angela Ayén-Rodríguez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hospital Universitario San Cecilio, 18016 Granada, Spain. Hauptthemen laut MEDLINE: Skin Neoplasms, Antineoplastic Agents, Basal Cell Carcinoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Basal cell carcinoma (BCC) is the most common type of skin cancer and can represent a therapeutic challenge in patients with locally advanced disease. Vismodegib is a hedgehog pathway inhibitor approved by the FDA for use in this type of tumor. We present a case series to describe our experience with the use of vismodegib.
Methods
A retrospective study that included patients treated with vismodegib at our dermatology unit was conducted. Monthly follow-up was performed, and we registered the clinical evolution and adverse reactions.
Results
A total of six patients with locally advanced BCCs were included (50% males and 50% females), with a mean age of 78.5 years old. The treatment was administered over a mean of 5 months. A complete response was observed in four cases and partial response in two cases. No recurrence was detected, with a median follow-up duration after discontinuation of 18 months. Most patients (83%) had at least one adverse event, and two needed dose adjustment temporarily or permanently to continue. The main adverse effect was muscle spasms (66.7%). The main limitation of our study was the small sample, which was not representative of the general population.
Conclusions
Vismodegib is a safe and effective treatment for locally advanced BCC, and its role in unresectable BCC seems to be an important option in these challenging cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Department, Hospital Universitario San Cecilio, 18016 Granada, Spain.
ORCID-Profile: Angela Ayén-Rodríguez, Ricardo Ruiz-Villaverde
Zitieren
APA
Ayén-Rodríguez, A., Linares-González, L., Llamas-Segura, C., Almazán-Fernández, F. M., & Ruiz-Villaverde, R. (2023). Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph20105824
Vancouver
Ayén-Rodríguez A, Linares-González L, Llamas-Segura C, Almazán-Fernández FM, Ruiz-Villaverde R. Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center. International Journal of Environmental Research and Public Health. 2023. doi:10.3390/ijerph20105824
BibTeX
@article{AynRodrguez2023,
author = {Ayén-Rodríguez, Angela and Linares-González, Laura and Llamas-Segura, Carlos and Almazán-Fernández, Francisco Manuel and Ruiz-Villaverde, Ricardo},
title = {Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center},
journal = {International Journal of Environmental Research and Public Health},
year = {2023},
doi = {10.3390/ijerph20105824}
}
EUVIMED